COLLEGEVILLE,Pennsylvania--12 Feb--PRNewswire-AsiaNet/InfoQuest
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), welcomes the decision by donor countries to focus on the importance of pneumococcal disease and to launch a pilot Advanced Market Commitment, which will help to bring the pneumococcal conjugate vaccine to developing countries.
"This financial pledge brings much needed attention to the global burden of pneumococcal disease," says Bernard Poussot, President, Chief Operating Officer and Vice Chairman, Wyeth. "We join the International Federation of
Wyeth is committed to helping to protect infants and young children against pneumococcal disease and currently markets the only pneumococcal conjugate vaccine, PREVENAR(TM), Pneumococcal Saccharide Conjugated Vaccine, Adsorbed, which has been incorporated into many childhood immunization programs around the world and has had a significant public health impact.
Recently, the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE), advocated for priority inclusion of PREVENAR in national immunization programs around the world. SAGE recommended that the vaccine be incorporated into immunization programs now, in view of the demonstrated vaccine efficacy and high disease burden, to help substantially reduce
mortality and morbidity.
In addition, Wyeth is now developing a 13-valent pneumococcal conjugate vaccine that targets additional serotypes. This investigational vaccine is currently undergoing clinical development and would potentially offer broader coverage against pneumococcal disease.
About Pneumococcal Disease
Wyeth Pharmaceuticals
SOURCE: Wyeth Pharmaceuticals
CONTACT: Natalie de Vane, +1-484-865-5139, or Valerie Bomberger,
+1-484-865-4188, both of Wyeth Pharmaceuticals; or Investor Contact: Justin
Victoria of Wyeth, +1-973-660-5340/
Web site: http://www.wyeth.com/
(WYE)
--Distributed by AsiaNet ( www.asianetnews.net )--